Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human CD163 Protein, His tag, 100 µg  

Recombinant Human CD163 Protein, His tag, 100 µg

Recombinant Human CD163 Protein (Ser 42 - Ser 1045), produced in human 293 cells (HEK293), His tag

Synonym
Recombinant Human protein, CD163, M130

More details

CD3-H52E8-100

Availability: within 7 days

420,00 €

Background
Scavenger receptor cysteine-rich type 1 protein M130 (CD163) is also known as hemoglobin scavenger receptor, which is a scavenger receptor for the hemoglobin-haptoglobin complex. CD163 has also been shown to mark cells of monocyte/macrophage lineage. A soluble form of the receptor exists in plasma, commonly denoted sCD163. sCD163 is generated by ectodomain shedding of the membrane bound receptor. sCD163 is upregulated in a large range of inflammatory diseases including liver cirrhosis, type 2 diabetes, macrophage activation syndrome, Gaucher's disease, sepsis, HIV infection, rheumatoid arthritis and Hodgkin Lymphoma.

Source
Recombinant Human CD163 Protein (Human CD163, His Tag) Ser 42 - Ser 1045 (Accession # Q86VB7) was produced in human 293 cells (HEK293) at ACROBiosystems.

Molecular Characterization
Human CD163, His Tag is fused with a polyhistidine tag at the C-terminus, and has a calculated MW of 110.4 kDa. The predicted N-terminus is Ser 42. DTT-reduced Protein migrates as 135-140 kDa in SDS-PAGE due to glycosylation.

Endotoxin
Less than 1.0 EU per μg of the Human CD163, His Tag by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for reconstitution instructions and specific concentrations.

Storage
Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C); After reconstitution under sterile conditions for 3 months (-70°C).

References

(1) Law S.K.A., et al., 1993, Eur. J. Immunol. 23:2320-2325.
(2) Matsushita N., et al., 2002, Clin. Exp. Immunol. 130:156-161.
(3) Ritter M., et al., 2001, Eur. J. Immunol. 31:999-1009.